|
Postively
Aware Index 2003
|
|
Subject
|
Issue | Page | |
|
Cardiovascular complications
|
|||
|
|
May/Jun
|
24
|
|
|
|
Nov/Dec
|
13
|
|
|
Children
|
|||
|
|
Sep/Oct
|
39
|
|
|
|
Sep/Oct
|
40
|
|
|
|
May/Jun
|
12
|
|
|
|
Mar/Apr
|
27
|
|
|
|
Nov/Dec
|
12
|
|
|
|
Mar/Apr
|
26
|
|
|
Clinical trials
|
|||
|
|
May/Jun
|
13
|
|
|
|
May/Jun
|
40
|
|
|
Combination therapy
|
|||
|
|
Jan/Feb
|
63
|
|
|
|
Jan/Feb
|
73
|
|
|
|
Jan/Feb
|
72
|
|
|
Commentary
|
|||
|
|
Mar/Apr
|
15
|
|
|
|
Jul/Aug
|
40
|
|
|
|
Nov/Dec
|
41
|
|
|
|
Jan/Feb
|
17
|
|
| Jul/Aug | 7 | ||
|
|
Mar/Apr
|
12
|
|
|
|
May/Jun
|
7
|
|
|
|
Sep/Oct
|
7
|
|
|
|
Nov/Dec
|
7
|
|
|
|
Sep/Oct
|
50
|
|
|
|
Mar/Apr
|
42
|
|
|
|
May/Jun
|
42
|
|
|
|
Jul/Aug
|
43
|
|
|
|
Nov/Dec
|
42
|
|
|
|
Mar/Apr
|
44
|
|
|
|
Jan/Feb
|
75
|
|
|
|
May/Jun
|
45
|
|
|
|
Sep/Oct
|
53
|
|
|
|
Mar/Apr
|
45
|
|
|
|
Mar/Apr
|
16
|
|
|
|
Jul/Aug
|
14
|
|
|
|
Sep/Oct
|
13
|
|
|
|
Mar/Apr
|
43
|
|
|
|
Jan/Feb
|
71
|
|
|
Conferences
|
|||
|
|
Jul/Aug
|
13
|
|
|
|
May/Jun
|
23
|
|
|
Cultural issues
|
|||
|
|
Sep/Oct
|
27
|
|
|
Drug compliance
|
|||
|
|
Jul/Aug
|
39
|
|
|
Drug interactions
|
|||
|
|
Jan/Feb
|
28
|
|
|
|
Jan/Feb
|
28
|
|
|
Drug side effects
|
|||
|
|
Jan/Feb
|
63
|
|
|
|
Jul/Aug
|
30
|
|
|
|
Nov/Dec
|
28
|
|
|
Drugs
|
|||
|
|
2003 HIV
drug chart (PDF, 2004 version)
|
Jan/Feb
|
40
|
|
|
May/Jun
|
13
|
|
|
|
May/Jun
|
14
|
|
|
|
Agenerase (amprenavir) fact
sheet (2004 version)
|
Jan/Feb
|
56
|
|
|
Jan/Feb
|
29
|
|
|
|
Atazanavir fact sheet (2004
version)
|
Jan/Feb
|
59
|
|
|
Jul/Aug
|
29
|
|
|
|
Combivir (AZT/3TC) fact sheet
(2004 version)
|
Jan/Feb
|
44
|
|
|
Nov/Dec
|
13
|
|
|
|
Coviracil (now named Emtriva)
/ FTC fact sheet (2004 version)
|
Jan/Feb
|
46
|
|
|
Crixivan (indinavir) fact sheet
(2004 version)
|
Jan/Feb
|
52
|
|
|
May/Jun
|
23
|
|
|
|
Mar/Apr
|
14
|
|
|
|
Jan/Feb
|
61
|
|
|
|
Sep/Oct
|
12
|
|
|
|
Epivir (3TC) fact sheet (2004
version)
|
Jan/Feb
|
42
|
|
|
Fortovase (saquinavir soft-gel)
fact sheet
|
Jan/Feb
|
55
|
|
|
Fuzeon (T-20) fact sheet (2004
version)
|
Jan/Feb
|
60
|
|
|
May/Jun
|
12
|
|
|
|
Hivid (ddc) fact sheet (2004 version)
|
Jan/Feb
|
38
|
|
|
Sep/Oct
|
8
|
|
|
|
Invirase (saquinavir hard-gel)
fact sheet (2004 version)
|
Jan/Feb
|
51
|
|
|
Sep/Oct
|
11
|
|
|
|
Kaletra (lopinavir/ritonavir)
fact sheet (2004 version)
|
Jan/Feb
|
57
|
|
|
Nov/Dec
|
14
|
|
|
|
Sep/Oct
|
12
|
|
|
|
Sep/Oct
|
11
|
|
|
|
Sep/Oct
|
20
|
|
|
|
Norvir (ritonavir) fact sheet
(2004 version)
|
Jan/Feb
|
53
|
|
|
Nov/Dec
|
14
|
|
|
|
Rescriptor (delavirdine) fact
sheet (2004 version)
|
Jan/Feb
|
48
|
|
|
Retrovir (AZT) fact sheet (2004
version)
|
Jan/Feb
|
36
|
|
|
Jul/Aug
|
12
|
|
|
|
May/Jun
|
12
|
|
|
|
Sustiva (efavirenz) fact sheet
(2004 version)
|
Jan/Feb
|
50
|
|
|
Nov/Dec
|
13
|
|
|
|
Sep/Oct
|
51
|
|
|
|
Nov/Dec
|
13
|
|
|
|
Tipranavir fact sheet (2004
version)
|
Jan/Feb
|
58
|
|
|
Trizivir (AZT/3TC/abacavir)
fact sheet (2004 version)
|
Jan/Feb
|
45
|
|
|
Sep/Oct
|
11
|
|
|
|
Videx & Videx EC (ddI) fact
sheet (2004 version)
|
Jan/Feb
|
37
|
|
|
Viracept (nelfinavir) fact sheet
(2004 version)
|
Jan/Feb
|
54
|
|
|
Jul/Aug
|
12
|
|
|
|
Viramune (nevirapine) fact sheet
(2004 version)
|
Jan/Feb
|
49
|
|
|
Viread (tenofovir) fact sheet
(2004 version)
|
Jan/Feb
|
47
|
|
|
Sep/Oct
|
8
|
|
|
|
Nov/Dec
|
32
|
|
|
|
Sep/Oct
|
25
|
|
|
|
Zerit (d4T) fact sheet (2004 version)
|
Jan/Feb
|
39
|
|
|
Mar/Apr
|
14
|
|
|
|
Ziagen (abacavir) fact sheet (2004
version)
|
Jan/Feb
|
43
|
|
Financial issues
|
|||
|
|
Sep/Oct
|
8
|
|
|
|
Jul/Aug
|
42
|
|
|
|
Jul/Aug
|
13
|
|
|
Hepatitis
|
|||
|
|
Nov/Dec
|
17
|
|
|
|
Nov/Dec
|
37
|
|
|
|
May/Jun
|
18
|
|
|
|
Jan/Feb
|
28
|
|
|
|
Jan/Feb
|
30
|
|
|
|
Jan/Feb
|
31
|
|
|
HIV education
|
|||
|
|
Jul/Aug
|
13
|
|
|
HIV prevention
|
|||
|
|
Jan/Feb
|
29
|
|
|
|
Sep/Oct
|
8
|
|
|
|
Jul/Aug
|
12
|
|
|
|
Jan/Feb
|
30
|
|
|
|
Jan/Feb
|
31
|
|
|
HIV research
|
|||
|
|
Jan/Feb
|
29
|
|
|
|
Jul/Aug
|
13
|
|
|
|
Jul/Aug
|
13
|
|
|
HIV testing
|
|||
|
|
Nov/Dec
|
17
|
|
|
|
Jan/Feb
|
30
|
|
|
HIV transmission
|
|||
|
|
Jan/Feb
|
30
|
|
|
|
Mar/Apr
|
14
|
|
|
|
Mar/Apr
|
15
|
|
|
|
May/Jun
|
23
|
|
|
HIV treatment
|
|||
|
|
May/Jun
|
31
|
|
|
|
Jan/Feb
|
32
|
|
|
|
Nov/Dec
|
17
|
|
|
|
Jan/Feb
|
69
|
|
|
|
Nov/Dec
|
12
|
|
|
|
Jan/Feb
|
34
|
|
|
Immune system
|
|||
|
|
Mar/Apr
|
14
|
|
|
|
May/Jun
|
16
|
|
|
|
Mar/Apr
|
41
|
|
|
International issues
|
|||
|
|
Mar/Apr
|
20
|
|
|
|
Mar/Apr
|
29
|
|
|
|
Mar/Apr
|
38
|
|
|
|
Nov/Dec
|
23
|
|
|
|
May/Jun
|
13
|
|
|
|
Nov/Dec
|
20
|
|
|
|
Mar/Apr
|
30
|
|
|
|
Mar/Apr
|
28
|
|
|
|
Mar/Apr
|
38
|
|
|
|
Mar/Apr
|
27
|
|
|
|
Nov/Dec
|
19
|
|
|
|
May/Jun
|
12
|
|
|
|
Mar/Apr
|
25
|
|
|
|
Nov/Dec
|
26
|
|
|
|
Mar/Apr
|
38
|
|
|
|
Mar/Apr
|
15
|
|
|
|
Mar/Apr
|
26
|
|
|
|
Mar/Apr
|
15
|
|
|
Interview
|
|||
|
|
Mar/Apr
|
17
|
|
|
Lifestyle
|
|||
|
|
May/Jun
|
12
|
|
|
Lipodystrophy
|
|||
|
|
Mar/Apr
|
32
|
|
|
|
Jan/Feb
|
28
|
|
|
|
Jan/Feb
|
29
|
|
|
Mental health
|
|||
|
|
Jul/Aug
|
25
|
|
|
|
Jul/Aug
|
38
|
|
|
Microbicides
|
|||
|
|
Jan/Feb
|
29
|
|
|
Minority issues
|
|||
|
|
Mar/Apr
|
31
|
|
|
Opportunistic infections
|
|||
|
|
Jan/Feb
|
29
|
|
|
|
Nov/Dec
|
13
|
|
|
Politics
|
|||
|
|
Jul/Aug
|
13
|
|
|
Post Exposure Prophylaxis (PEP)
|
|||
|
|
Jan/Feb
|
30
|
|
|
Pregnancy
|
|||
|
|
Jan/Feb
|
30
|
|
|
|
Sep/Oct
|
45
|
|
|
|
Sep/Oct
|
33
|
|
|
|
Sep/Oct
|
43
|
|
|
|
Jan/Feb
|
29
|
|
|
Prison issues
|
|||
|
|
Jul/Aug
|
12
|
|
|
|
May/Jun
|
13
|
|
|
Resistance
|
|||
|
|
May/Jun
|
12
|
|
|
|
Mar/Apr
|
37
|
|
|
|
Nov/Dec
|
17
|
|
|
Resources
|
|||
|
|
Jan/Feb
|
31
|
|
|
|
Jan/Feb
|
66
|
|
|
|
Sep/Oct
|
8
|
|
|
|
Jan/Feb
|
30
|
|
|
|
Jul/Aug
|
13
|
|
|
Rural issues
|
|||
|
|
Jul/Aug
|
17
|
|
|
Sexually Transmitted Infections
|
|||
|
|
Jan/Feb
|
30
|
|
|
|
Jan/Feb
|
30
|
|
|
Structured Treatment Interruptions (STIs)
|
|||
|
|
Sep/Oct
|
17
|
|
|
Substance use
|
|||
|
|
Jul/Aug
|
32
|
|
|
|
May/Jun
|
12
|
|
|
Tuberculosis
|
|||
|
|
Nov/Dec
|
35
|
|
|
Vaccines
|
|||
|
|
May/Jun
|
13
|
|
|
|
May/Jun
|
13
|
|
|
Women
|
|||
|
|
Sep/Oct
|
35
|
|
|
|
May/Jun
|
38
|
|
|
|
Nov/Dec
|
13
|
|
|
|
May/Jun
|
12
|
|
|
|
Mar/Apr
|
39
|
|